Protecting People and the Environment

Recently Pfizer announced the completion of a $1.25 billion “sustainability” bond, a first for Pfizer and the biopharmaceutical industry. This public and financial commitment underscores a sentiment I know to be true—that how we do business is as important as the medicines and vaccines we work to deliver to those who depend on us.

This focus, on not just what we do, but how and why we do it, has new significance as the world responds to a once-in-a-generation global pandemic. First responders and essential workers are working day and night to combat COVID-19. Unfortunately, other diseases and global health challenges are not patiently waiting in the wings. And so, we forge ahead for patients.

Proceeds from the sustainability bond will help manage the company’s environmental impact and support increased patient access to Pfizer’s medicines and vaccines, especially among underserved populations, and strengthen healthcare systems. Our investments will help drive and enhance long-standing strategies related to the company’s support of the United Nations’ Sustainable Development Goals, notably #3: Good health and well-being, and #13: Climate action.

Pfizer colleagues feel passionately about our environmental stewardship and health equity, and it’s a goal that Albert Bourla and the entire Pfizer leadership team is committed to delivering.